AlphaVax, Inc.

Description

Overview AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $110 million, with 75% coming from corporate partner and grant funding, and has advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing alphavaccines. The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines.

Fact sheet

Products & services

Similar companies nearby